Related Experiment Video
Updated: Jul 9, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Production and comprehensive quality control of recombinant human Interleukin-1beta: a case study for a process
Helena Block1, Jan Kubicek, Jörg Labahn
1QIAGEN GmbH, Qiagen Strasse 1, 40724 Hilden, Germany.
Abstract:
We describe an efficient strategy to produce high-quality proteins by using a single large IMAC chromatography column and enzymatic His-tag removal via the TAGZyme system in pilot scale. Numerous quality assays demonstrated a high purity of the final product, the human cytokine Interleukin-1beta (IL-1beta). The protein preparation was apparently free of host cell proteins, endotoxins, protease, and aggregates. The N-terminal amino acid sequence of IL-1beta was in full agreement with the natural mature form of IL-1beta. The homogeneity of the product was further shown by X-ray structure determination which confirmed the previously solved structure of the protein. We propose the applied workflow as a strategy for industrial production of protein-based biopharmaceuticals.
Related Concept Videos
Production of Pharmaceuticals
Upstream Processing

